News coverage about Arbutus Biopharma (NASDAQ:ABUS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arbutus Biopharma earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.509327645321 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Arbutus Biopharma (ABUS) traded down $0.05 during trading hours on Friday, hitting $5.05. 154,006 shares of the stock traded hands, compared to its average volume of 196,214. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 52-week low of $2.35 and a 52-week high of $8.25.

Several analysts have weighed in on ABUS shares. Leerink Swann reissued a “market perform” rating and issued a $5.00 price target (up from $4.00) on shares of Arbutus Biopharma in a research note on Tuesday, November 7th. ValuEngine raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. BidaskClub downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. Wedbush reissued an “outperform” rating and issued a $9.00 price target on shares of Arbutus Biopharma in a research note on Wednesday, September 20th. Finally, Zacks Investment Research raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $13.00.

In other news, insider Michael J. Sofia sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Arbutus Biopharma (ABUS) Earns Daily Media Sentiment Rating of 0.04” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/arbutus-biopharma-abus-earns-daily-media-sentiment-rating-of-0-04/1754069.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.